When are the cardiovascular and stroke risks too high? Pharmacotherapy for stroke prophylaxis

Area of Science:

• Cardiology
• Neurology
• Clinical Risk Assessment

Background:

• Stroke is a leading cause of death and disability globally.
• Cardioembolic strokes, frequently associated with atrial fibrillation (AF), present a poorer prognosis and higher recurrence rates.
• Effective risk stratification is crucial for managing stroke, particularly in AF patients.

Purpose of the Study:

• To review general and AF-specific scores for assessing cardiovascular and stroke risks.
• To summarize current recommendations for antithrombotic therapy in stroke prevention.
• To aid clinical decision-making in identifying patients who require specific interventions.

Main Methods:

• Literature review of stroke risk assessment scores.
• Analysis of scores applicable to atrial fibrillation (AF) patients.
• Synthesis of evidence regarding antithrombotic treatment guidelines.

Main Results:

• Various risk scores aid in identifying factors necessitating medical intervention.
• Integrated risk scores with visual aids can enhance clinical decision-making.
• Patients with prior stroke/TIA require antiplatelet or anticoagulant therapy based on stroke type.

Conclusions:

• Risk stratification scores are vital for guiding stroke prevention strategies.
• Anticoagulation is recommended for primary stroke prevention in AF patients with additional risk factors.
• Tailored antithrombotic therapy is essential for managing cardioembolic stroke risk.